Technology for quantitating protein phosphorylation

描述（由申请人提供）：本提案的目标是开发一种用于疾病管理的检测多种蛋白质标记物的新技术。在这个项目中，该技术将用于在一次测试中分析许多蛋白质的磷酸化状态。目前使用的大多数临床检测都是基于对单一疾病标志物的检测，这限制了它们的准确性。相比之下，一个单一的测试来评估多种疾病标志物将显著提高疾病测试的分析和预测能力。因此，开发一种高通量和低成本的多标记物检测技术是一个迫切的、尚未满足的医疗需求。最近的研究表明，某些蛋白质磷酸化事件可能发生在特定的疾病状态。该项目将开发一种高通量蛋白质检测技术，基于表位的定量使用抗体和t7聚合酶（EpiQUANT），用于一次确定正常和病变组织样本中众多蛋白质的磷酸化模式。的诊断潜力

DESCRIPTION (provided by applicant): The objective of this proposal is to develop a novel technology for detecting multiple protein markers for disease management. In this project, the technology will be used in profiling the phosphorylation state of numerous proteins in a single test. Most clinical tests currently in use are based on the detection of single disease markers, which limits their accuracy. In contrast, a single test to evaluate multiple disease markers would significantly enhance the analytical and predictive powers of disease testing. Therefore, developing a high throughput and cost effective technology for multi-marker detection is an urgent, unmet, medical need. Recent research suggests that certain protein phosphorylation events are likely to occur during specific diseased states. This program will develop a high throughput protein detection technology, Epitope-based Quantification Using Antibodies and T7-polymerase (EpiQUANT), for determining the phosphorylation patterns of numerous proteins at once in normal and diseased tissue samples. The diagnostic potential of EpiQUANT technology will be evaluated using clinical samples. Until now, most phospho-specific antibodies have been polyclonal in nature, which severely limits their diagnostic utility. The advent of Epitomics' rabbit monoclonal antibody (RabMAb) technology enables, for the first time, the reliable production of monoclonal phospho-specific antibodies with consistent quality and an unlimited supply. EpiQUANT will represent a new level of throughput through the novel, synergistic combination of two proven technologies-antibody binding and DNA microarray detection. If successfully developed, EpiQUANT technology and diagnostic kits will enable the simultaneous, systematic analysis of phosphorylated proteins and relate these patterns directly to diseased versus healthy states. These reagent kits will be commercialized to the research community and further developed into diagnostic products.